(Reuters) - Novavax Inc said on Monday its longtime chief executive officer, Stanley Erck, would retire and be succeeded by industry veteran John Jacobs, at a time when the COVID-19 vaccine maker looks to catch up with larger rivals.
(Reuters) – Novavax Inc said on Monday its longtime chief executive officer, Stanley Erck, would retire and be succeeded by industry veteran John Jacobs, at a time when the COVID-19 vaccine maker looks to catch up with larger rivals.
Novavax shares were up about 5% in premarket trade.
Jacobs takes over the role effective Jan. 23. He joins Novavax from Harmony Biosciences, where he served as CEO since June 2018.
Erck, who has been at the helm of the company since 2011, was responsible for bringing Novavax’s COVID vaccine, its first commercial product, to the market.
However, the shot has been plagued by manufacturing snags, regulatory delays and sluggish uptake amid a global supply glut for vaccines and waning demand.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Saumyadeb Chakrabarty and Shailesh Kuber)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: